Successful management of histoplasmosis with novel triazole antifungals: a brief report
Journal of Antimicrobial Chemotherapy · 2026
DOI: 10.1093/jac/dkag370 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2026. Verfasst von Carla Concha Fuentes und 11 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Department, Hospital Clinic of Barcelona, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Carrer de Villarroe…. Hauptthemen laut MEDLINE: Triazoles, Antifungal Agents, Histoplasmosis. Die Arbeit nennt 18 Literaturangaben. Gefördert von: Ministerio de Sanidad y Consumo, Instituto de Salud Carlos III, Instituto de Salud Carlos III (ISCIII), European Union.
Abstract (Originalsprache)
Objectives
Standard therapy for histoplasmosis is often limited by drug–drug interactions, toxicity and variable pharmacokinetics. We report clinical experience using the novel triazoles posaconazole and isavuconazole as alternative treatment options.
Methods
A retrospective case series was conducted. We analysed six cases of confirmed histoplasmosis (identified by culture, histopathology or PCR) in patients hospitalized in Barcelona, Spain, between 2017 and 2022. Patients received posaconazole delayed-release tablets (300 mg daily) or isavuconazole capsules (200 mg daily) as primary or step-down therapy. Complete response was defined as the resolution of all attributable signs and symptoms with microbiological clearance and/or radiological improvement when available.
Results
The cohort included immunocompromised and immunocompetent patients with disseminated (n = 3), localized (n = 2) and chronic cavitary pulmonary (n = 1) histoplasmosis. Comorbidities included HIV, chronic lymphocytic leukaemia and corticosteroid use. Novel triazoles were utilized as step-down therapy after liposomal amphotericin B (LAmB) induction (n = 5) or as primary oral therapy (n = 1) for a median duration of 11.75 months. One patient with severe intestinal involvement received isavuconazole following itraconazole-induced hepatotoxicity and short-course LAmB. All six patients (100%) achieved complete clinical, radiological and/or mycological response without evidence of toxicity or relapse during 1–5 years of follow-up.
Conclusions
These findings contribute real-world evidence supporting the potential role of posaconazole and isavuconazole as alternative therapeutic options for confirmed histoplasmosis given their favourable safety profile, long-term tolerability and clinical outcomes in our series. Larger multicentre comparative studies are needed to better define the role of novel triazoles compared with the current standard of care (itraconazole).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Infectious Diseases Department, Hospital Clinic of Barcelona, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Carrer de Villarroel 170, Barcelona 08036, Spain.
- Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona (UB), Barcelona, Spain.
- Infectious Diseases Department, Vall d'Hebron University Hospital, Barcelona, Spain.
- Microbiology Department, Hospital Clinic, University of Barcelona, Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain.
ORCID-Profile: Joaquín Burgos-Cibrián, Antonio Gallardo-Pizarro, Ana Martinez-Urrea, Marta Bodro, Alex Soriano
Förderung
- Ministerio de Sanidad y Consumo, Instituto de Salud Carlos III
- Instituto de Salud Carlos III (ISCIII)
- European Union
Zitieren
APA
Concha Fuentes, C., Castiella-Aranzasti, A., Burgos-Cibrián, J., Monzo-Gallo, P., Gallardo-Pizarro, A., Terrones-Campos, C., Martinez-Urrea, A., Galindo Contador, C., Vergara, A., Bodro, M., Soriano, A., & Garcia-Vidal, C. (2026). Successful management of histoplasmosis with novel triazole antifungals: a brief report. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkag370
Vancouver
Concha Fuentes C, Castiella-Aranzasti A, Burgos-Cibrián J, Monzo-Gallo P, Gallardo-Pizarro A, Terrones-Campos C, et al. Successful management of histoplasmosis with novel triazole antifungals: a brief report. Journal of Antimicrobial Chemotherapy. 2026. doi:10.1093/jac/dkag370
BibTeX
@article{ConchaFuentes2026,
author = {Concha Fuentes, Carla and Castiella-Aranzasti, Ainhoa and Burgos-Cibrián, Joaquín and Monzo-Gallo, Patricia and Gallardo-Pizarro, Antonio and Terrones-Campos, Cynthia and Martinez-Urrea, Ana and Galindo Contador, Carolina and Vergara, Andrea and Bodro, Marta and Soriano, Alex and Garcia-Vidal, Carolina},
title = {Successful management of histoplasmosis with novel triazole antifungals: a brief report},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2026},
doi = {10.1093/jac/dkag370}
}
EUVIMED